跳至主要内容
临床试验/NCT00456612
NCT00456612终止1 期

Phase I/II Study of Fractionated CyberKnife Stereotactic Radiosurgery for High Grade Gliomas in Elderly Patients With Poor Performance Status

Beth Israel Deaconess Medical Center2 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2007年2月最近更新:
适应症

试验速览

阶段
1 期
状态
终止
入组人数
4
试验地点
2
主要终点
The Percent Progression -Free Survival at 6 Months Will be Tabulated

研究概览

简要总结

Conventional radiation for 6 weeks is not well tolerated by the elderly. Shorter courses (over 3-5 weeks) of radiation have been shown to be equivalent in outcome the elderly- particularly in patients who are generally in poor performance status (KPS<70). Fractionated Cyberknife Radiosurgery can deliver equivalent doses in 5 treatments providing the same tumor control in a much shorter and tolerable schedule improving their quality of their short life.

To assess the tolerability of Cyberknife Radiosurgery for High Grade Gliomas in Elderly with poor performance status.

Secondary:

Assessment of local control rate, progression free survival, overall survival, quality of life and toxicity and steroid dependence in this population with this regime.

详细描述

Conventional radiation for 6 weeks is not well tolerated by the elderly. Shorter courses (over 3-5 weeks) of radiation have been shown to be equivalent in outcome the elderly- particularly in patients who are generally in poor performance status (KPS<70). Fractionated Cyberknife Radiosurgery can deliver equivalent doses in 5 treatments providing the same tumor control in a much shorter and tolerable schedule improving their quality of their short life.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
66 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histopathologically confirmed newly diagnosed glioblastoma multiforme or Anaplastic Glioma (WHO Grade III) by surgical excision or biopsy.
  • Patient must recover from the effects of surgery, post-operative infection, or other complications.
  • Therapy should start within 5 weeks of surgery
  • Must have an estimated survival of > 8 weeks.
  • Age > 65 years.
  • Must have a pre- and post operative contrast enhanced MRI scans
  • Laboratory values within the following limits: ANC (absolute neutrophil count) >/= 1500 cell/ul Platelets >/= 100x 10(3)/ul, Hemoglobin >/= 9g/dl, Serum Creatinine ≤ 1.5mg/dl., Serum total Bilirubin </= 1.5 x upper limit of normal (ULN), SGOT/SGPT </= 2.5x ULN, Albumin >/= 3g/dl.

排除标准

  • Histology grade less than Anaplastic Glioma ( WHO Grade III).
  • Recurrent malignant glioma.
  • Tumor involving the Brain stem.
  • Any detected tumor foci beyond the cranial vault.
  • Major medical or psychiatric illness, which in the investigator's opinion will prevent administration or completion of the protocol therapy.
  • Prior malignancies, except for non-melanomatous skin cancers, or carcinoma in situ of uterus, cervix or bladder, unless disease free for > 5 years.
  • Prior chemotherapy for the current disease.

结局指标

主要结局

The Percent Progression -Free Survival at 6 Months Will be Tabulated

时间窗: 6 months

Progression Free Survival

时间窗: consent to prgression or death

次要结局

  • Response, Median Time to Tumor Progression,Overall Survival, Percent Overall Survival at 1 Year Will be Tabulated.(1year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Anand Mahadevan

Radiation Oncologist

Beth Israel Deaconess Medical Center

研究点 (2)

Loading locations...

相似试验